NLS Immunicum

Immunicum announces an update on its Phase I/II study in liver cancer and reports that the first patient in the extended part of the study has been treated with the cancer immune primer. The first patient in the extended part of the study has been treated in the firstline setting with the cancer immune primer INTUVAX. Immunicum initiated a […]

Immunicum has started its phase II clinical study of Intuvax, a therapeutic vaccine for metastatic kidney cancer. Intuvax is based on a technology developed by Immunicum’s research director and founder Alex K-Parra. It involves using dendritic cells from healthy blood donors in order to get the patients ‘ own immune systems to eliminate cancer cells. […]

Sweden’s Athena Prize, healthcare’s largest prize for clinical research, was awarded this year to physician and Associate Professor Alex Karlsson-Parra, of Uppsala University Hospital and founder of the company Immunicum. The company specializes in developing therapeutic cancer vaccines. The prize, which consists of a research grant of $150 000, was awarded in December at the Swedish […]

Immunicum has announced continued compelling survival data from its phase I/II-study in metastatic renal cell carcinoma. The data showed a median survival for patients with poor prognosis (five patients) currently at 13 months compared to the expected median survival of 8-9 months for patients treated with tyrosine kinase inhibitors. One patient was excluded from the survival study […]

Immunicum announces positive survival data from a clinical phase I/II-study with the therapeutic cancer vaccine INTUVAX for the treatment of metastatic renal cancer. The clinical phase I/II-study, initiated in February 2012, includes a total of 12 patients, each treated with two intratumoral injections/vaccinations with INTUVAX, two weeks apart, after which their cancer affected kidney, as […]